References
- Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137:1742–1750.
- Bernstein JA, Kavati A, Tharp MD, et al. Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of ‘realworld’ evidence. Exp Opin Biol Ther. 2018;18:425–448.
- Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA²LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Update. Allergy. 2018;73:1393–1414.
- Balbino B, Conde E, Marichal T, et al. Approaches to target IgE antibodies in allergic diseases. Pharmacol Ther. 2018;191:50–64.
- Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–935.
- Gomez G, Jogie-Brahim S, Shima M, et al. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced FcεRI on human skin mast cells. J Immunol. 2007;179:1353–1361.
- Ghazanfar M, Holm J, Thomsen S. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study. J Eur Acad Dermatol Venereol. 2018;32:1761–1767.
- Gallo C, Vighi G, Schroeder J, et al. Chronic urticaria atopic dermatitis and celiac disease. Am J Gastroenterol. 1992;87:1684.
- Kolkhir P, Borzova E, Grattan C, et al. Autoimmune comorbidity in chronic spontaneous urticaria: A systematic review. Autoimmun Rev. 2017;16:1196–1208.